ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

At this year's recently concluded ESMO conference, new developments related to the PARP inhibitor talazoparib in precision diagnosis and treatment were announced. Precision diagnosis has become a leading trend in the field of prostate cancer, and biomarker research is receiving increasing attention. In this context, this publication invited Professor Guiming Zhang from Qingdao University Affiliated Hospital, a well-known young expert in the field of prostate cancer, for an in-depth interview to explain the three new developments related to talazoparib's precision treatment recently announced at ESMO. Here, we provide a summary of the interview for the readers.
ESMO Exclusive Interview | Professor HuiyanLuo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors

ESMO Exclusive Interview | Professor HuiyanLuo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors

The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into the front lines to witness international advancements and to witness the progress of China's anti-tumor efforts on the global stage. Professor Huiyan Luo from Sun Yat-sen University Cancer Center presented a crucial oral presentation (Abstract ID: 1026MO) at this conference. In this on-site interview, Professor Huiyan Luo shared insights into the study of the treatment of advanced solid tumors using the dual-target antibody SHR-1701, which targets PD-L1 and TGF-βRII, in combination with the VEGF inhibitor bevacizumab, as well as her thoughts on future directions for the treatment of advanced tumors. This article compiles the relevant content for readers.